Comparative assessment of angiotensin ii type 1 receptor blockers in the treatment of acute myocardial infarction: surmountable vs. insurmountable antagonist
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Hae Chang | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.contributor.author | Ahn, Youngkeun | - |
dc.contributor.author | Chae, Shung Chull | - |
dc.contributor.author | Hur, Seung Ho | - |
dc.contributor.author | Hong, Taek Jong | - |
dc.contributor.author | Kim, Young Jo | - |
dc.contributor.author | Seong, In Whan | - |
dc.contributor.author | Chae, Jei Keon | - |
dc.contributor.author | Rhew, Jay Young | - |
dc.contributor.author | Chae, In Ho | - |
dc.contributor.author | Cho, Myeong Chan | - |
dc.contributor.author | Bae, Jang Ho | - |
dc.contributor.author | Rha, Seung Woon | - |
dc.contributor.author | Kim, Chong Jin | - |
dc.contributor.author | Choi, Donghoon | - |
dc.contributor.author | Jang, Yang Soo | - |
dc.contributor.author | Yoon, Junghan | - |
dc.contributor.author | Chung, Wook Sung | - |
dc.contributor.author | Cho, Jeong Gwan | - |
dc.contributor.author | Seung, Ki Bae | - |
dc.contributor.author | Park, Seung Jung | - |
dc.date.accessioned | 2021-09-05T12:27:53Z | - |
dc.date.available | 2021-09-05T12:27:53Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-01-01 | - |
dc.identifier.issn | 0167-5273 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/99573 | - |
dc.description.abstract | Background: The mechanisms of antagonism vary between the angiotensin II type 1 receptor blockers (ARBs): insurmountable antagonism and surmountable antagonism. Recent retrospective observational studies suggest that ARBsmay not have equivalent benefits in various clinical situations. The aim of this study was to compare the effect of two categories of ARBs on the long-term clinical outcomes of patients with acute myocardial infarction (AMI). Methods: We analyzed the large-scale, prospective, observational Korea Acute Myocardial Infarction Registry study, which enrolled 2740 AMI patients. They divided by the prescription of surmountable ARBs or insurmountable ARBs at discharge. Primary outcome was major adverse cardiac events (MACEs), defined as a composite of cardiac death, nonfatal MI, and re-percutaneous coronary intervention, coronary artery bypass graft surgery. Results: In the overall population, the MACEs rate in 1 year was significantly higher in the surmountable ARB group (14.3% vs. 11.2%, p = 0.025), which was mainly due to increased cardiac death (3.3% vs. 1.9%, p = 0.031). Matching by propensity-score showed consistent results (MACEs rate: 14.9% vs. 11.4%, p = 0.037). In subgroup analysis, the insurmountable ARB treatment significantly reduced the incidence of MACEs in patients with left ventricular ejection fraction greater than 40%, with a low killip class, with ST segment elevation MI, and with normal renal function. Conclusions: In our study, insurmountable ARBs were more effective on long-term clinical outcomes than surmountable ARBs in patients with AMI. (C) 2013 Published by Elsevier Ireland Ltd. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.subject | HEART-FAILURE | - |
dc.subject | AT(1)-RECEPTOR BLOCKERS | - |
dc.subject | COST-EFFECTIVENESS | - |
dc.subject | AT(1) RECEPTOR | - |
dc.subject | CANDESARTAN | - |
dc.subject | LOSARTAN | - |
dc.subject | BLOCKADE | - |
dc.subject | ASSOCIATION | - |
dc.subject | MORTALITY | - |
dc.subject | OUTCOMES | - |
dc.title | Comparative assessment of angiotensin ii type 1 receptor blockers in the treatment of acute myocardial infarction: surmountable vs. insurmountable antagonist | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung Woon | - |
dc.identifier.doi | 10.1016/j.ijcard.2013.07.146 | - |
dc.identifier.scopusid | 2-s2.0-84891019906 | - |
dc.identifier.wosid | 000329124100016 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CARDIOLOGY, v.170, no.3, pp.291 - 297 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 170 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 291 | - |
dc.citation.endPage | 297 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | HEART-FAILURE | - |
dc.subject.keywordPlus | AT(1)-RECEPTOR BLOCKERS | - |
dc.subject.keywordPlus | COST-EFFECTIVENESS | - |
dc.subject.keywordPlus | AT(1) RECEPTOR | - |
dc.subject.keywordPlus | CANDESARTAN | - |
dc.subject.keywordPlus | LOSARTAN | - |
dc.subject.keywordPlus | BLOCKADE | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordAuthor | Angiotensin | - |
dc.subject.keywordAuthor | Myocardial infarction | - |
dc.subject.keywordAuthor | Prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.